MESOBLAST LIMITED ORDINARY (MSB) Short Interest
MESOBLAST LIMITED ORDINARY (ASX:MSB) had 8.30% of shares reported as short positions as of 16 July 2026, representing 107,447,420 shares. MESOBLAST LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4MSB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Mesoblast
Latest MSB news
All news- Why Are Mesoblast (ASX:MSB) and Supply Network (ASX:SNL) Suddenly Back on Value Watchlists?
kalkine
- Mesoblast (ASX:MSB) Climbs as Global Biotech Dealmaking Heats Up
kalkine
- Mesoblast Announces Expiry of 1,237,237 MSBAI Employee Options Due to Unmet Vesting Conditions
kalkine
- Mesoblast (ASX:MSB) hits 300 patients in the trial that could dwarf Ryoncil - Stocks Down Under
googlenews
- Notification of cessation of securities - MSB
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss MSB
Start a research thread or post the first pulse update